U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Malignant Lymphoma, Large Cell, Cleaved and Non-Cleaved

MedGen UID:
311937
•Concept ID:
C1521845
•
Neoplastic Process

Definition

Antiquated term describing follicular (nodular) or diffuse non-Hodgkin lymphomas that are composed of a mixture of large cells: large cleaved cells, with irregular nuclei without visible nucleoli; and large non-cleaved cells (centroblasts), having a rounder nucleus with two to three small, peripherally placed nucleoli and a small amount of basophilic cytoplasm. The follicular variants represent mature B-cell lymphomas, whereas the diffuse variants can be either mature B- or mature T-cell lymphomas. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMalignant Lymphoma, Large Cell, Cleaved and Non-Cleaved

Professional guidelines

PubMed

Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
Nastoupil LJ, Bartlett NL
J Clin Oncol 2023 Feb 1;41(4):903-913. Epub 2022 Dec 12 doi: 10.1200/JCO.22.01848. PMID: 36508700
Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U
Cancer Treat Rev 2022 Nov;110:102443. Epub 2022 Jul 31 doi: 10.1016/j.ctrv.2022.102443. PMID: 35933930
MALT lymphoma: epidemiology, clinical diagnosis and treatment.
Violeta Filip P, Cuciureanu D, Sorina Diaconu L, Maria Vladareanu A, Silvia Pop C
J Med Life 2018 Jul-Sep;11(3):187-193. doi: 10.25122/jml-2018-0035. PMID: 30364585Free PMC Article

Recent clinical studies

Etiology

Epidemiology and etiology of diffuse large B-cell lymphoma.
Wang SS
Semin Hematol 2023 Nov;60(5):255-266. Epub 2023 Nov 27 doi: 10.1053/j.seminhematol.2023.11.004. PMID: 38242772Free PMC Article
Diffuse Large B-Cell Lymphoma.
Sehn LH, Salles G
N Engl J Med 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612. PMID: 33657296Free PMC Article
Gastrointestinal non-Hodgkin lymphomas.
Olszewska-Szopa M, Wróbel T
Adv Clin Exp Med 2019 Aug;28(8):1119-1124. doi: 10.17219/acem/94068. PMID: 31414733
Diffuse large B-cell lymphoma.
Li S, Young KH, Medeiros LJ
Pathology 2018 Jan;50(1):74-87. Epub 2017 Nov 20 doi: 10.1016/j.pathol.2017.09.006. PMID: 29167021
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA
Crit Rev Oncol Hematol 2013 Aug;87(2):146-71. Epub 2013 Jan 30 doi: 10.1016/j.critrevonc.2012.12.009. PMID: 23375551

Diagnosis

Intravascular Large B-Cell Lymphoma.
Cheng JW, Li JH
N Engl J Med 2023 Dec 7;389(23):2188. doi: 10.1056/NEJMicm2307122. PMID: 38055255
Intravascular Large B-Cell Lymphoma.
Davis JW, Auerbach A, Crothers BA, Lewin E, Lynch DT, Teschan NJ, Schmieg JJ
Arch Pathol Lab Med 2022 Sep 1;146(9):1160-1167. doi: 10.5858/arpa.2021-0165-RA. PMID: 34979566
Diffuse large B-cell lymphoma.
Li S, Young KH, Medeiros LJ
Pathology 2018 Jan;50(1):74-87. Epub 2017 Nov 20 doi: 10.1016/j.pathol.2017.09.006. PMID: 29167021
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA
Crit Rev Oncol Hematol 2013 Aug;87(2):146-71. Epub 2013 Jan 30 doi: 10.1016/j.critrevonc.2012.12.009. PMID: 23375551
Relapsed/refractory diffuse large B-cell lymphoma.
Friedberg JW
Hematology Am Soc Hematol Educ Program 2011;2011:498-505. doi: 10.1182/asheducation-2011.1.498. PMID: 22160081

Therapy

Limited-stage diffuse large B-cell lymphoma.
Hawkes EA, Barraclough A, Sehn LH
Blood 2022 Feb 10;139(6):822-834. doi: 10.1182/blood.2021013998. PMID: 34932795
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C
Blood 2017 Oct 19;130(16):1800-1808. Epub 2017 Aug 3 doi: 10.1182/blood-2017-03-769620. PMID: 28774879Free PMC Article
ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS, Czuczman MS
Am Soc Clin Oncol Educ Book 2015:e449-57. doi: 10.14694/EdBook_AM.2015.35.e449. PMID: 25993209
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA
Crit Rev Oncol Hematol 2013 Aug;87(2):146-71. Epub 2013 Jan 30 doi: 10.1016/j.critrevonc.2012.12.009. PMID: 23375551
Relapsed/refractory diffuse large B-cell lymphoma.
Friedberg JW
Hematology Am Soc Hematol Educ Program 2011;2011:498-505. doi: 10.1182/asheducation-2011.1.498. PMID: 22160081

Prognosis

Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025.
Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Jon E Arnason
Leuk Lymphoma 2022 Jan;63(1):54-63. Epub 2021 Sep 11 doi: 10.1080/10428194.2021.1975188. PMID: 34510995
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, Wang Z, Zhang M, Wu J, Liu H, Zhang P, Yang S, Zhou Z, Zheng H, Song Y, Zhu J
Cancer Med 2021 Feb;10(3):999-1011. Epub 2020 Dec 31 doi: 10.1002/cam4.3686. PMID: 33382529Free PMC Article
Management of relapsed/refractory DLBCL.
Sarkozy C, Sehn LH
Best Pract Res Clin Haematol 2018 Sep;31(3):209-216. Epub 2018 Jul 23 doi: 10.1016/j.beha.2018.07.014. PMID: 30213390
Diffuse large B-cell lymphoma.
Li S, Young KH, Medeiros LJ
Pathology 2018 Jan;50(1):74-87. Epub 2017 Nov 20 doi: 10.1016/j.pathol.2017.09.006. PMID: 29167021
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Mounier N, El Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas RO, Delarue R, Sonet A, Beaussart P, Petrella T, Castaigne S, Bologna S, Salles G, Rahmouni A, Gaulard P, Haioun C
Haematologica 2013 Nov;98(11):1726-31. Epub 2013 Jun 10 doi: 10.3324/haematol.2013.090597. PMID: 23753028Free PMC Article

Clinical prediction guides

Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma.
Liang XJ, Song XY, Wu JL, Liu D, Lin BY, Zhou HS, Wang L
Int J Biol Sci 2022;18(4):1313-1327. Epub 2022 Jan 9 doi: 10.7150/ijbs.67892. PMID: 35280688Free PMC Article
Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks.
Ponzoni M, Campo E, Nakamura S
Blood 2018 Oct 11;132(15):1561-1567. Epub 2018 Aug 15 doi: 10.1182/blood-2017-04-737445. PMID: 30111607
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article
Diffuse large B-cell lymphoma.
Li S, Young KH, Medeiros LJ
Pathology 2018 Jan;50(1):74-87. Epub 2017 Nov 20 doi: 10.1016/j.pathol.2017.09.006. PMID: 29167021
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA
Crit Rev Oncol Hematol 2013 Aug;87(2):146-71. Epub 2013 Jan 30 doi: 10.1016/j.critrevonc.2012.12.009. PMID: 23375551

Recent systematic reviews

Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M
Transplant Cell Ther 2024 Jan;30(1):77.e1-77.e15. Epub 2023 Oct 27 doi: 10.1016/j.jtct.2023.10.017. PMID: 37890589
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Kim J, Cho J, Yoon SE, Kim WS, Kim SJ
Cancer Res Treat 2023 Jul;55(3):1031-1047. Epub 2023 Mar 13 doi: 10.4143/crt.2022.1658. PMID: 36915243Free PMC Article
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S
Transplant Cell Ther 2022 Jun;28(6):294-302. Epub 2022 Mar 11 doi: 10.1016/j.jtct.2022.03.006. PMID: 35288347Free PMC Article
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M
Cochrane Database Syst Rev 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PMID: 34515338Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...